NEWS

logo.gif (1594 bytes)

NEWS

Press Releases NEWS PAGE COMPANY INDEX Press Releases

 

Monsanto initiates first large-scale, genome-wide application of Incyte's DNA microarrays for functional genomics
Monsanto will access up to 50,000 DNA microarrays

Palo Alto, California, and St. Louis, Missouri

May 18, 1998

Incyte Pharmaceuticals Inc. and Monsanto Company announced today that they have entered into an agreement whereby Incyte will provide Monsanto with broad access to Incyte's gene expression microarray technology. The three-year agreement provides Monsanto scientists with the ability to analyze up to 500 million gene expression data points using Incyte's GEM™ microarrays. Financial terms of the agreement were not disclosed.

Under terms of the agreement, Incyte will provide data to Monsanto from custom and pre-fabricated DNA microarrays, software to manage and analyze the data, and consulting and software support. "The ability to measure gene expression in a highly parallel fashion across plant, animal and human genomes will expedite the discovery of our life sciences products of tomorrow," said Ganesh Kishore, assistant chief scientist and chief biotechnologist of Monsanto.
"These tools will enable Monsanto scientists to better understand the potential role of genes in
treating or preventing disease in humans, in enhancing crop quality and crop yield, and in promoting better human health through improved nutrition in foods. These capabilities are a critical piece of our overall effort in the area of functional genomics, an important link between gene structure and product innovation."

With access to data from up to 50,000 DNA microarrays, Monsanto scientists can routinely use
this technology across their life sciences projects. This technology will provide an unprecedented
understanding of how genes respond both individually and as networks. Monsanto will have the
ability to select microarrays containing comprehensive gene sets from all of Incyte's genomic databases as well as genes available from Monsanto's own databases.

"This agreement with Monsanto will accelerate the achievement of our goal to provide every Incyte
gene on a microarray and thus make whole-genome scanning a reality," said Roy A. Whitfield, Chief Executive Officer of Incyte. "The large-scale production volume contemplated in this agreement will allow our partners to expand the application of DNA microarrays beyond discovery to pharmacology, toxicology, clinical trial analysis and agricultural programs."

Incyte and Monsanto have a pre-existing agreement providing Monsanto with access to Incyte's broad platform of genomic databases, genomic data management software, and biological reagents including the LifeSeq human gene sequence and expression database, the LifeSeq FL database of full-length genes, the LifeSeq Atlas gene mapping database, the LifeSeq GeneAlbum cDNA clone reagent set, the PathoSeq microbial database, the ZooSeq animal gene sequence and expression database, and the LifeTools bioinformatics software data management system.

As a life sciences company, Monsanto is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. The company's 21,900 employees worldwide make and market high-value agricultural products, pharmaceuticals and food ingredients.

Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies  designed to aid in the understanding of the molecular basis of disease. Incyte's platform includes database products, genomic data management software tools, microarrays, and related reagents and services which Incyte provides to the pharmaceutical and biotechnology industries to assist their drug discovery and development efforts. Incyte employs over 650 people located at its headquarters in Palo Alto, California, and operations in Fremont, California, St. Louis, Missouri and Cambridge, UK.

N1681

.0

Copyright © 1999 SeedQuest - All rights reserved